DeCure's autonomous Cancer AI scientist is researching a drug-repurposing hypothesis for malignant hypertension — screening already-approved drugs against its 6-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleMalignant hypertension maps to a 6-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for malignant hypertension is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
Molecular view
calcium voltage-gated channel subunit alpha1 D (CACNA1D) — CACNA1D is one of the genes genetically linked to this disease in Open Targets — shown as context, not as a drug target we're pursuing: no approved-drug candidate for this disease is yet corroborated in the literature we found.
Loading structure…
helix sheet clrdrag to rotate · scroll to zoom
RCSB Protein Data Bank · entry 7UHG · 3.0 Å · ligand CHOLESTEROL (CLR). Experimental structure, not a prediction.
What the evidence adds up to
Malignant hypertension is a hypertensive emergency with rapid disease progression and poor prognosis. A 2022 narrative review states that significant knowledge gaps remain about its pathogenesis and treatment, and calls for pooled future efforts at improving treatment and prognosis. No new trial data, survival figures, or response rates are provided in that review.
A 1993 study of 23 patients with previous malignant hypertension (fundus hypertonicus grades III or IV) in the Gothenburg area found that the frequency of T lymphocytes and their baseline thymidine incorporation were significantly depressed compared with control subjects. The patient group also had a decreased proliferative response to concanavalin-A but not to phytohaemagglutinin, and an increased frequency of antinuclear antibodies. Human leucocyte antigen B15 tended to occur more frequently in patients with malignant and non-malignant hypertension than in control subjects, especially when a family history of hypertension was considered. The authors concluded that immune mechanisms are involved in malignant hypertension, either secondary to vascular damage or as a primary abnormality.
A 1977 report notes that effective treatment available in the last two decades had changed the outlook remarkably, especially in malignant hypertension, and that there was increasing evidence that less severe forms of hypertension benefit from blood pressure control. No specific drug, survival statistic, or response rate from that era is given in the abstract.
What is still missing is a modern, adequately powered prospective trial that tests a specific repurposed agent in malignant hypertension, with clearly defined endpoints and patient stratification by immune or genetic markers. The 2022 review confirms that the basic pathogenesis and treatment gaps remain unfilled, and no funding or trial design for such a study is described in these abstracts.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
Journal of the American Heart Association · 2022 · 66 citations · open access
Malignant Hypertension: Current Perspectives and Challenges
AbstractMalignant hypertension is a hypertensive emergency, with rapid disease progression and poor prognosis. Although recognized as a separate entity more than a century ago, significant knowledge gaps remain about its pathogenesis and treatment. This narrative review summarizes current viewpoints, research gaps, and challenges with a view to pooling future efforts at improving treatment and prognosis.
Abnormal immune function in malignant hypertension
AbstractOBJECTIVE: To investigate the extent to which the immune system is influenced in patients with previous malignant hypertension. DESIGN: Twenty-three patients with malignant hypertension (fundus hypertonicus grades III or IV) in the Gothenburg area were studied over a 3-year period. After treatment had been instituted they were investigated to establish the function of the cellular immune system (number of T lymphocytes and the proliferative response to T-cell mitogens), human leucocyte antigens A, B and C and frequency of autoantibodies. METHODS: The numbers of T lymphocytes were quantified as erythrocyte rosettes. Lymphocyte-stimulation tests were carried out using the T-cell mitogens phytohaemagglutinin and concanavalin-A. Autoantibodies were determined with immunoassay techniques and leucocyte A, B and C antigens with a lymphocytotoxicity test. RESULTS: The frequency of T lymphocytes and their baseline thymidine incorporation were significantly depressed in patients with previously malignant hypertension compared with control subjects. The group with malignant hypertension also had a decreased proliferative response to concanavalin-A but not to phytohaemagglutinin, and they had an increased frequency of antinuclear antibodies. Human leucocyte antigen B15 tended to occur more frequently in patients with malignant and non-malignant hypertension than in control subjects, especially if a family history of hypertension was taken into consideration. CONCLUSION: The results from the present study indicate that immune mechanisms are involved in malignant hypertension, either secondary to the vascular damage or as a primary abnormality.
AbstractHypertension has been found to imply a disease entity since the beginning of this century. Effective treatment available in the last two decades has changed the outlook remarkably, especially in malignant hypertension. There are more and more evidence that less severe forms of hypertension will benefit from keeping the blood pressure under control.
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
